Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: April 06, 2026
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
Journal: Nature medicine
Published: January 29, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.
Journal: Cancer research communications
Published: September 24, 2025
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.
Journal: Cancer research communications
Published: September 24, 2025
Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab.
Journal: Future science OA
Published: November 20, 2024
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 17, 2023
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Journal: Journal for immunotherapy of cancer
Published: September 07, 2023
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 19, 2022
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Journal: Breast cancer research and treatment
Published: May 04, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Journal: Breast cancer research and treatment
Published: August 23, 2021
Last Updated: 09/26/2026